Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
<p>Abstract</p> <p>Purpose</p> <p>To evaluate a panel of pretreatment clinical and laboratory parameters in metastatic melanoma (MM) in order to verify their impact on response and survival in a single prospective multi-institutional phase III study comparing out-patien...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2003-12-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/1/1/13 |
id |
doaj-c7cfc047941c4a5b884ef5ffb699308b |
---|---|
record_format |
Article |
spelling |
doaj-c7cfc047941c4a5b884ef5ffb699308b2020-11-24T21:52:51ZengBMCJournal of Translational Medicine1479-58762003-12-011113Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialCasamassima AddolorataBrugnara SalvatoreFreschi AntonioLabianca RobertoRomanini AntonellaSileni VannaRavaioli AlessandraGuida MicheleLorusso VitoNanni OrianaRidolfi Ruggero<p>Abstract</p> <p>Purpose</p> <p>To evaluate a panel of pretreatment clinical and laboratory parameters in metastatic melanoma (MM) in order to verify their impact on response and survival in a single prospective multi-institutional phase III study comparing out-patient chemotherapy (CT) vs bioCT.</p> <p>Methods</p> <p>A total of 176 patients were randomised to receive CT (cisplatin, dacarbazine, optional carmustine) or bioCT (the same CT followed by subcutaneous IL-2 plus intramuscular α-IFN-2b). Pretreatment total leucocytes, lymphocytes, eosinophyls, C-reactive protein (CRP), lactate dehydrogenase (LDH), erytrosedimentation rate (ESR), and fibrinogen were analyzed. Some clinical parameters (performance status, age, sex, and disease site) were also considered. As we found a positive trend for bio-CT with no statistical significance in OR (25.3% vs 20.2%) and OS (11 Mo vs 9.5 Mo), all analyses are stratified by treatment arm.</p> <p>Results</p> <p>In univariate analysis, higher value of lymphocytes percentage (P < .0001), lower value of total leucocytes (P=.005), CRP (P=.003), LHD (P < .0001), ESR (P < .027), fibrinogen (P < .0001), and no liver disease were strongly related to a better survival. In a multivariate analysis, using the Cox proportional hazards model, only fibrinogen (P=.004), LDH (P=.009) and liver disease (P=.04) were found to have an independent role on clinical outcome in metastatic melanoma patients.</p> <p>Conclusion</p> <p>Liver disease and higher LDH and fibrinogen levels had an important impact on survival in MM patients. In particular, fibrinogen has been recently reconsidered both for its determinant role in the host hemostatic system, and for its capability to provide protection against NK and LAK-cell-induced lysis. These observations could have some important implications for therapeutic approaches, in particular when immunological strategies are used.</p> http://www.translational-medicine.com/content/1/1/13 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Casamassima Addolorata Brugnara Salvatore Freschi Antonio Labianca Roberto Romanini Antonella Sileni Vanna Ravaioli Alessandra Guida Michele Lorusso Vito Nanni Oriana Ridolfi Ruggero |
spellingShingle |
Casamassima Addolorata Brugnara Salvatore Freschi Antonio Labianca Roberto Romanini Antonella Sileni Vanna Ravaioli Alessandra Guida Michele Lorusso Vito Nanni Oriana Ridolfi Ruggero Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial Journal of Translational Medicine |
author_facet |
Casamassima Addolorata Brugnara Salvatore Freschi Antonio Labianca Roberto Romanini Antonella Sileni Vanna Ravaioli Alessandra Guida Michele Lorusso Vito Nanni Oriana Ridolfi Ruggero |
author_sort |
Casamassima Addolorata |
title |
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial |
title_short |
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial |
title_full |
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial |
title_fullStr |
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial |
title_full_unstemmed |
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial |
title_sort |
fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: imi (italian melanoma inter-group) trial |
publisher |
BMC |
series |
Journal of Translational Medicine |
issn |
1479-5876 |
publishDate |
2003-12-01 |
description |
<p>Abstract</p> <p>Purpose</p> <p>To evaluate a panel of pretreatment clinical and laboratory parameters in metastatic melanoma (MM) in order to verify their impact on response and survival in a single prospective multi-institutional phase III study comparing out-patient chemotherapy (CT) vs bioCT.</p> <p>Methods</p> <p>A total of 176 patients were randomised to receive CT (cisplatin, dacarbazine, optional carmustine) or bioCT (the same CT followed by subcutaneous IL-2 plus intramuscular α-IFN-2b). Pretreatment total leucocytes, lymphocytes, eosinophyls, C-reactive protein (CRP), lactate dehydrogenase (LDH), erytrosedimentation rate (ESR), and fibrinogen were analyzed. Some clinical parameters (performance status, age, sex, and disease site) were also considered. As we found a positive trend for bio-CT with no statistical significance in OR (25.3% vs 20.2%) and OS (11 Mo vs 9.5 Mo), all analyses are stratified by treatment arm.</p> <p>Results</p> <p>In univariate analysis, higher value of lymphocytes percentage (P < .0001), lower value of total leucocytes (P=.005), CRP (P=.003), LHD (P < .0001), ESR (P < .027), fibrinogen (P < .0001), and no liver disease were strongly related to a better survival. In a multivariate analysis, using the Cox proportional hazards model, only fibrinogen (P=.004), LDH (P=.009) and liver disease (P=.04) were found to have an independent role on clinical outcome in metastatic melanoma patients.</p> <p>Conclusion</p> <p>Liver disease and higher LDH and fibrinogen levels had an important impact on survival in MM patients. In particular, fibrinogen has been recently reconsidered both for its determinant role in the host hemostatic system, and for its capability to provide protection against NK and LAK-cell-induced lysis. These observations could have some important implications for therapeutic approaches, in particular when immunological strategies are used.</p> |
url |
http://www.translational-medicine.com/content/1/1/13 |
work_keys_str_mv |
AT casamassimaaddolorata fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT brugnarasalvatore fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT freschiantonio fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT labiancaroberto fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT romaniniantonella fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT silenivanna fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT ravaiolialessandra fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT guidamichele fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT lorussovito fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT nannioriana fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial AT ridolfiruggero fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial |
_version_ |
1725874504979185664 |